These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 5006193)

  • 21. [Value and reliability of new methods of detection of arrhythmia. Evaluation of the efficacity of chloro-acetyl-ajmaline].
    Coumel P; Bouvrain Y; Attuel P
    Sem Hop Ther; 1974 Dec; 50(10):635-42. PubMed ID: 4465912
    [No Abstract]   [Full Text] [Related]  

  • 22. [Acute ajmaline poisoning. Study of 7 cases].
    Bouffard Y; Roux H; Perrot D; Ducluzeau R; Page Y; Lehot JJ; Bouletreau P; Motin J
    Arch Mal Coeur Vaiss; 1983 Jul; 76(7):771-7. PubMed ID: 6412646
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Cardiac toxicity of ajmaline. Comparison of acute voluntary poisoning with complications of the ajmaline test].
    Caramella JP; Guerot C; Valere PE; Tricot R; Bismuth C; Riboulet G
    Arch Mal Coeur Vaiss; 1982 May; 75(5):613-20. PubMed ID: 6810791
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Liver damage due to N-propyl-ajmalin bitartrate (NPAB)].
    Henning H; Vogel HM; Ihlenfeld J; Buchegger K; Lüders CJ
    Z Gastroenterol; 1975 Sep; 13(5):501-6. PubMed ID: 1189511
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Agranulocytosis associated with ajmalin therapy.
    Wilson JH; Cazemier T; Nieweg HO
    Acta Med Scand; 1971; 190(1-2):35-9. PubMed ID: 5099125
    [No Abstract]   [Full Text] [Related]  

  • 26. [Electrophysiological effects of chloroacetyl ajmaline in Wolff-Parkinson-White syndrome].
    Touboul P; Gressard A; Atallah G; Chatelain MT; Delahaye JP
    Arch Mal Coeur Vaiss; 1978 Jul; 71(7):808-15. PubMed ID: 102281
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Jaundice caused by ajmaline: pathogenetic theory concerning 5 cases].
    Giani E; Cestari C; Lomazzi A; Magni S; Pioltelli P; Ratti L; Dinelli CA
    Clin Ter; 1981 Oct; 99(2):155-64. PubMed ID: 7318369
    [No Abstract]   [Full Text] [Related]  

  • 28. [Anti-arrhythmia action of a new semi-synthetic derivative of ajmaline: N-propyl-ajmaline bitartrate].
    Cristallo E; Landriscina B; De Luca I; Albrizio A; Palma B; Losignore M
    Boll Soc Ital Cardiol; 1975; 20(4):327-33. PubMed ID: 1231912
    [No Abstract]   [Full Text] [Related]  

  • 29. Life-threatening ventricular arrhythmias during ajmaline challenge in patients with Brugada syndrome: incidence, clinical features, and prognosis.
    Conte G; Sieira J; Sarkozy A; de Asmundis C; Di Giovanni G; Chierchia GB; Ciconte G; Levinstein M; Casado-Arroyo R; Baltogiannis G; Saenen J; Saitoh Y; Pappaert G; Brugada P
    Heart Rhythm; 2013 Dec; 10(12):1869-74. PubMed ID: 24055942
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Ajmaline in the management of cardiac arrhythmias.
    Ilyas M
    J Pak Med Assoc; 1981 Jul; 31(7):153-5. PubMed ID: 6792399
    [No Abstract]   [Full Text] [Related]  

  • 31. [Symposium on anti-arrhythmic drugs of the Swedish Society of Cardiology].
    Lakartidningen; 1973 Dec; 70(50):4665-77. PubMed ID: 4152516
    [No Abstract]   [Full Text] [Related]  

  • 32. [Anti-arrhythmic activity of 17-monochloroacetylajmaline as compared with that of 17-21-dichloroacetylajmaline. Experimental and clinical study].
    Capra C; Pretolani E
    Minerva Cardioangiol; 1973 Dec; 21(12):789-820. PubMed ID: 4780270
    [No Abstract]   [Full Text] [Related]  

  • 33. Paradoxic acceleration of ventricular rate after therapy with lidocaine and ajmaline. Findings in two patients with supraventricular tachyarrhythmia.
    Klein HO; Segni ED; Kaplinsky E
    Chest; 1977 Apr; 71(4):531-3. PubMed ID: 852326
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Intraindividual comparison of intravenous ajmaline and quinidine in patients with sustained ventricular tachycardia: effects on normal myocardium and on arrhythmia characteristics.
    Lengfelder W; Senges J; Rizos I; Jauernig R; Brachmann J; von Ohlshausen K; Kübler W
    Eur Heart J; 1985 Apr; 6(4):312-22. PubMed ID: 4029187
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Treatment of arrhythmias].
    Witzel L; Soballa G
    Fortschr Med; 1973 Mar; 91(7):287-9. PubMed ID: 4124325
    [No Abstract]   [Full Text] [Related]  

  • 36. Management of untreatable ventricular arrhythmias during pharmacologic challenges with sodium channel blockers for suspected Brugada syndrome.
    Poli S; Toniolo M; Maiani M; Zanuttini D; Rebellato L; Vendramin I; Dametto E; Bernardi G; Bassi F; Napolitano C; Livi U; Proclemer A
    Europace; 2018 Feb; 20(2):234-242. PubMed ID: 28521022
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Ajmaline in non-responders to lidocaine with malignant ventricular arrhythmia after thrombolytic therapy in acute myocardial infarction.
    Köppel C
    Intensive Care Med; 1991; 17(5):306-7. PubMed ID: 1939881
    [No Abstract]   [Full Text] [Related]  

  • 38. [Therapeutic results using prajmalium bitartrate, with special reference to tolerance and dosage in arrhythmic patients with a history of hepatotoxicity].
    Ardjah H
    Med Welt; 1979 Jan; 30(2):65-9. PubMed ID: 82899
    [No Abstract]   [Full Text] [Related]  

  • 39. Medical treatment of cardiac arrhythmias.
    Bender F
    Naunyn Schmiedebergs Arch Pharmakol; 1971; 269(2):272-97. PubMed ID: 4397724
    [No Abstract]   [Full Text] [Related]  

  • 40. [Preliminary clinical studies on the antiparkinson effects of 17-monochloroacetylajmaline].
    Errichiello G; Maglione S
    Minerva Med; 1974 May; 65(41):2357-9. PubMed ID: 4602984
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.